HEFEI, Chine, 19 juin 2023 /PRNewswire/ — TG ImmunoPharma Co. (TGI), une société de biotechnologie de premier plan spécialisée dans le développement de nouvelles thérapies immuno-oncologiques, a le plaisir d’annoncer que la FDA a autorisé l’essai clinique du TGI-6, son anticorps…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.